Expertise in
23
conditions

Dr. Luciano Costa

Hematology
UAB Hospital Birmingham
619 19th St S, 
Birmingham, AL 
Offers Telehealth
Expertise in
23
conditions
UAB Hospital Birmingham
619 19th St S, 
Birmingham, AL 

Overview

Luciano Costa is a Hematologist in Birmingham, Alabama. Dr. Costa is highly rated in 23 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 221 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in AL

Hospital Affiliations

University Of Alabama Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UAB Hospital Birmingham
619 19th St S, Birmingham, AL 35249

Additional Areas of Focus

Dr. Costa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug, Procedure
Study Drug: Fludarabine
Study Phase: Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
View 5 Less Clinical Trials

221 Total Publications

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: December 09, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Amitkumar Mehta
Hematology
Expertise in
30
conditions
Dr. Amitkumar Mehta
Hematology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.2 miles away)
205-801-8415
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amitkumar Mehta is a Hematologist in Birmingham, Alabama. Dr. Mehta is highly rated in 30 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy.

Andres Torres
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-996-6074
Languages Spoken:
English
See accepted insurances

Andres Torres is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Torres is highly rated in 23 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Breast Cancer, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
24
conditions
Dr. Pankit Vachhani
Hematology
Expertise in
24
conditions
Dr. Pankit Vachhani
Hematology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.2 miles away)
205-975-0412
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pankit Vachhani is a Hematologist in Birmingham, Alabama. Dr. Vachhani is highly rated in 24 conditions, according to our data. His top areas of expertise are Myelofibrosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Luciano Costa

How do I make an appointment with Dr. Luciano Costa?

You can book an appointment with Dr. Luciano Costa by calling their office at 205-934-4011. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Luciano Costa a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Luciano Costa is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Luciano Costa specialize in?

While Dr. Luciano Costa is a Hematology, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Plasmacytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Luciano Costa participate in research or clinical trials?

Yes. Dr. Luciano Costa has published 221 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Luciano Costa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Luciano Costa accept my insurance?

Dr. Luciano Costa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 205-934-4011 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Costa's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile